The immunogenicity of tumors has been established. Aspecific stimulation of immunity, such
as by cytokine therapy, has been shown to induce durable clinical remissions in metastatic …

Cancer immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit.
It can be passive, that is, transfer of immune effector cells (T cells) or proteins (antibodies), or …

Dendritic cells (DC) are professional antigen-presenting cells whose primary function is the
initiation of immune response. Based on the finding that the immune system usually fails to …

Dendritic cells (DCs) are the most potent professional antigen-presenting cells, capable of
initiating proper adaptive immune responses. Although tumor-infiltrating DCs are able to …

A growing list of defined tumor-antigens opens the way to antigen specific immunotherapy of
cancer. However current approaches are often limited in their potential to induce an effective …

Human tumors express a number of protein antigens that can be recognized by T cells, thus
providing potential targets for cancer immunotherapy. Dendritic cells (DCs) are rare …

According to the GLOBOCAN reports, there were about 12.7 million cancer cases and 7.6
million cancer deaths in 2008, and the cancer burden continues to increase worldwide [1]. At …

The characterization of tumorassociated antigens recognized by human T lymphocytes in a
major histocompatibility complex (MHC) restricted fashion has opened new possibilities for …

Dendritic cells (DCs) initiate and regulate immune responses. Numerous studies in mice
showed that tumor antigens-loaded DCs are able to induce therapeutic and protective anti …

Antigen presentation is a critical regulatory element for the induction of cellular immune
responses. Thus, one of the principal current goals of tumor immunotherapy is to control and …